Author Page for David I. Marks

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

A Phase 3 Study of Remestemcel-L versus Placebo Added to Second Line Therapy in Patients with Steroid Refractory Acute Graft Versus Host Disease

Number of pages: 31 Posted: 19 Mar 2019

Partow Kebriaei, Jack Hayes, Andrew Daly, Joseph P. Uberti, David I. Marks, Robert Soiffer, Edmund K. Waller, Elizabeth Burke, Donna Skerrett, Elizabeth Shpall and Paul J. Martin

University of Texas at Houston - MD Anderson Cancer Center, Mesoblast, University of Calgary - Tom Baker Cancer Center, Karmanos Cancer Institute, University Hospitals Bristol, Harvard University - Dana-Farber Cancer Institute, Emory University - Emory University Hospital, Mesoblast, Mesoblast, University of Texas at Houston - MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center

Downloads 156 (477,517)

Citation 2

View PDF
Download

David I. Marks

University Hospitals Bristol

1

156

2

Scholarly Papers (1)

A Phase 3 Study of Remestemcel-L versus Placebo Added to Second Line Therapy in Patients with Steroid Refractory Acute Graft Versus Host Disease

Abstract: